Published on
October 5, 2017
- 12:00 GMT
Dermira Completes Patient Enrollment in Two Phase 3 Pivotal Trials of Olumacostat Glasaretil for the Treatment of Acne Vulgaris
- Phase 3 pivotal trials enrolled a total of 1,503 patients - Topline efficacy and safety results expected in first quarter of 2018 MENLO PARK, Calif., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
